Sugi Predict

Sugi Predict / Targets / MAP4K3

MAP4K3

Mitogen-activated protein kinase kinase kinase kinase 3 · Q8IVH8 · MAP4K3 on Sugi Atlas →

19,815 patent compounds predicted against MAP4K3, 14,073 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Crizotinib Crizotinib (SCHEMBL93829) 1.00 7/20
Crizotinib Crizotinib (SCHEMBL94020) 1.00 7/20
SCHEMBL487829 SCHEMBL487829 0.53 5/20
SCHEMBL487725 SCHEMBL487725 0.47 5/20
SCHEMBL487739 SCHEMBL487739 0.42 5/20
SCHEMBL487708 SCHEMBL487708 0.46 4/20
SCHEMBL371886 SCHEMBL371886 0.60 3/20
SCHEMBL372007 SCHEMBL372007 0.56 3/20
SCHEMBL372225 SCHEMBL372225 0.56 3/20
SCHEMBL371939 SCHEMBL371939 0.55 3/20
SCHEMBL372271 SCHEMBL372271 0.55 3/20
SCHEMBL487833 SCHEMBL487833 0.50 3/20
SCHEMBL487589 SCHEMBL487589 0.48 3/20
SCHEMBL319361 SCHEMBL319361 0.47 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL321751) 0.46 3/20
SCHEMBL487818 SCHEMBL487818 0.43 3/20
SCHEMBL487777 SCHEMBL487777 0.43 3/20
SCHEMBL487572 SCHEMBL487572 0.42 3/20
SCHEMBL487754 SCHEMBL487754 0.38 3/20
Capivasertib Capivasertib (SCHEMBL390243) 1.00 2/20

Clinical trials — most relevant to MAP4K3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP4K3 binder may also engage these)

ProteinNameSimilarity
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 1.000 landscape →
Q924I2 — 1.000 Q924I2 →
Q99JP0 — 1.000 Q99JP0 →
Q8BPM2 — 1.000 Q8BPM2 →
P34908 — 0.986 P34908 →
Q8QFR2 — 0.984 Q8QFR2 →
Q04982 — 0.984 Q04982 →
PI4KB Phosphatidylinositol 4-kinase beta 0.984 landscape →
P62205 — 0.984 P62205 →
P28028 — 0.984 P28028 →
Q641K1 — 0.983 Q641K1 →
P70218 — 0.983 P70218 →
Q9BXB4 — 0.983 Q9BXB4 →
P39447 — 0.982 P39447 →
B1MTG7 — 0.982 B1MTG7 →
Q8BWW9 — 0.982 Q8BWW9 →
Q5SQE2 — 0.982 Q5SQE2 →
PKN2 Serine/threonine-protein kinase N2 0.981 landscape →
TBK1 Serine/threonine-protein kinase TBK1 0.981 landscape →
B2KI64 — 0.981 B2KI64 →
E9Q4Z2 — 0.981 E9Q4Z2 →
Q95168 — 0.981 Q95168 →
Q9UPW5 — 0.981 Q9UPW5 →
Q921C3 — 0.981 Q921C3 →
Q8CI95 — 0.981 Q8CI95 →
Q07139 — 0.980 Q07139 →
MAP3K5 Mitogen-activated protein kinase kinase kinase 5 0.980 landscape →
B0KWC1 — 0.980 B0KWC1 →
O35099 — 0.980 O35099 →
A4IID4 — 0.980 A4IID4 →